# PAZOPANIB Efficacy and Tolerance in Desmoids Tumors

> **NCT01876082** · PHASE2 · COMPLETED · sponsor: **Institut Bergonié** · enrollment: 72 (actual)

## Conditions studied

- Progressive Desmoids Tumors

## Interventions

- **DRUG:** PAZOPANIB treatment
- **DRUG:** Active Comparator: Vinblastine and Methotrexate

## Key facts

- **NCT ID:** NCT01876082
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-18
- **Primary completion:** 2018-03
- **Final completion:** 2019-09
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01876082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01876082, "PAZOPANIB Efficacy and Tolerance in Desmoids Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01876082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*